Results 221 to 230 of about 58,375 (292)

Enhanced Radionuclide Therapy via the Conjugation of Pentadecanoic Acids With ²²⁵Ac- and ¹⁷⁷Lu-Labeled RGD Peptides. [PDF]

Cancer Sci
Yoshimoto M, Wada SI, Yoshii Y, Hanadate S, Inaki A, Fujii H.   +5 more
europepmc   +1 more source

On the reduction of imaging time-points for dosimetry in radionuclide therapy. [PDF]

EJNMMI Phys
Gustafsson J, Taprogge J.
europepmc   +1 more source

Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy. [PDF]

Eur J Nucl Med Mol Imaging
Mendes F, Terry SYA, Spiegelberg D, Cornelissen B, Bolcaen J, Nonnekens J, European Working group of Radiobiology of Molecular Radionuclide Therapy.   +6 more
europepmc   +1 more source

Molecular Mechanisms of Antitumor Effect in Targeted Alpha-radionuclide Therapy

Yasuhiro Ohshima
openalex   +2 more sources

Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy

, 2016
Latifa Rbah‐Vidal, A. Vidal, Emilie M.F. Billaud, Sophie Besse, Isabelle Ranchon‐Cole, Florence Mishellany, Y. Perrot, Lydia Maigne, Nicole Moins, Jean‐Luc Guerquin‐Kern, Françoise Degoul, Jean‐Michel Chezal, Philippe Auzeloux, Elisabeth Miot-Noirault   +13 more
openalex   +1 more source

Tumor sink effect on melanin-ligand [¹³¹I]ICF01012 in melanoma and its implications for targeted radionuclide therapy. [PDF]

EJNMMI Res
Jouberton E, Besse S, Billoux T, Auzeloux P, Schmitt S, Chezal JM, Sas N, Noirault L, Auriol M, Levesque S, Delmas M, Chaussin B, Chautard E, Miot-Noirault E, Rouanet J, Cachin F.   +15 more
europepmc   +1 more source

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors. [PDF]

Pharmaceuticals (Basel)
Leupe H, Cauwenbergh M, Cleeren F, Dekervel J, Verslype C, Deroose CM.   +5 more
europepmc   +1 more source

Editorial: Women in radionuclide therapy: 2023

Frontiers in Nuclear Medicine
Egesta Lopci, Federica Matteucci
doaj   +1 more source

Intra-arterial peptide receptor radionuclide therapy (IA-PRRT) in patients with SSTR-expressing neuroendocrine neoplasms: short- and long-term safety and efficacy for up to 13 years. [PDF]

Theranostics
Zhang J, Mensel B, Baum RP.
europepmc   +1 more source

Targeted Radionuclide Therapy Activates Prodrugs for Treating Metastasis. [PDF]

ACS Cent Sci
Guo Z, Wang X, Han Y, Shen S, Tian P, Hu Y, Ding Z, Fu Q, Liu Z.   +8 more
europepmc   +1 more source